Bristol-myers squibb company ce (CELG-RI) 2025Q4 financial report shows revenue of 12.5B USD, with a YoY growth rate of 1.30%. This figure indicates that Bristol-myers squibb company ce (CELG-RI)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of Bristol-myers squibb company ce (CELG-RI)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.